Fosun Pharma’s COVID-19 Vaccine Starts Clinical Phase, Approved by Chinese NMPA
COVID-19 and China
Image credit: EqualOcean

Fosun Pharma’s COVID-19 preventive vaccine has been approved by the National Medical Products Administration to enter clinical trials. If the vaccine passes Phase III, it can officially go to the market into a commercial-stage. Considering the large-scale impact brought by the pandemic, there is a considerable consumption market for prevention.

The progress is the fruit of cooperative work. Exclusively authorized this March by BioNTech SE (BNTX:Nasdaq), Germany-based biotechnology, Fosun Pharma has been developing an mRNA-based vaccine for COVID-19 and owns the related commercial rights.

Latest Updates:

See Also

Communicate Directly with the Author!

Ask the author questions about the copied text

Research Reports
Editor's Picks